MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Phase 3
Completed
Conditions
Glabellar Frown Lines
Interventions
First Posted Date
2007-02-02
Last Posted Date
2011-10-26
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
256
Registration Number
NCT00430963
Locations
🇩🇪

Merz Pharmaceuticals GmbH, Frankfurt, Germany

Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery

Phase 3
Completed
Conditions
Unequal Length of Limbs; Congenital
Lower Extremity Deformities, Congenital
Interventions
Drug: saline injection
First Posted Date
2006-12-15
Last Posted Date
2014-12-23
Lead Sponsor
Shriners Hospitals for Children
Target Recruit Count
125
Registration Number
NCT00412035
Locations
🇺🇸

Alfred I.duPont Hospital for Children, Wilmington, Delaware, United States

🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

🇨🇦

Shriners Hospital for Children, Montreal, Quebec, Canada

A Study Of BOTOX For The Treatment Of Glabellar Lines

Phase 3
Completed
Conditions
Glabellar Lines
Interventions
First Posted Date
2006-12-07
Last Posted Date
2017-05-31
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
256
Registration Number
NCT00408785
Locations
🇨🇳

GSK Investigational Site, Shanghai, China

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

Phase 3
Completed
Conditions
Cervical Dystonia
Interventions
First Posted Date
2006-12-04
Last Posted Date
2013-07-19
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
233
Registration Number
NCT00407030

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Phase 3
Completed
Conditions
Blepharospasm
Interventions
First Posted Date
2006-12-04
Last Posted Date
2013-03-15
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
109
Registration Number
NCT00406367
Locations
🇺🇸

Baylor College of Medicine, Houston, Texas, United States

🇨🇦

David King, MD - Private Practice, Halifax, Nova Scotia, Canada

Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA)

Phase 2
Completed
Conditions
Knee Pain
Interventions
Drug: Normal Saline
First Posted Date
2006-11-23
Last Posted Date
2018-05-21
Lead Sponsor
Minneapolis Veterans Affairs Medical Center
Target Recruit Count
54
Registration Number
NCT00403273
Locations
🇺🇸

Minneapolis VA Medical Center, Minneapolis, Minnesota, United States

Pilot Study to Assess the Efficacy of Botulinum Toxin A Treatments on Pain and Disability in Sub-Acute Low Back Pain

Phase 4
Terminated
Conditions
Low Back Pain
Interventions
First Posted Date
2006-10-06
Last Posted Date
2009-03-05
Lead Sponsor
United States Department of Defense
Registration Number
NCT00384371
Locations
🇺🇸

Walter Reed Army Medical Center, Washington, District of Columbia, United States

Placebo Controlled Trial of Botulinum Toxin for Gastroparesis

Not Applicable
Completed
Conditions
Gastroparesis
Interventions
First Posted Date
2006-09-07
Last Posted Date
2015-06-09
Lead Sponsor
Temple University
Target Recruit Count
32
Registration Number
NCT00372970
Locations
🇺🇸

Temple University Hospital, Philadelphia, Pennsylvania, United States

Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease

Phase 2
Conditions
Eye Diseases
First Posted Date
2006-09-01
Last Posted Date
2007-02-27
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
50
Registration Number
NCT00370734
Locations
🇮🇷

Babak Babsharif, MD, Tehran, Iran, Islamic Republic of

A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Neuropathic Foot Pain

Not Applicable
Completed
Conditions
Diabetes Mellitus
Neuropathic Pain
First Posted Date
2006-06-13
Last Posted Date
2011-07-26
Lead Sponsor
Taipei Medical University Hospital
Target Recruit Count
30
Registration Number
NCT00336349
Locations
🇨🇳

Chaur-Jong Hu, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath